| -blockers: Mandatory for everyone with heart failure? K Swedberg Heart Failure Updates, 91-108, 2003 | | 2003 |
| (the metoprolol in dilated cardiomyopathy (MDC) trial study group): Beneficial effects of metoprolol in idopathic dilated cardiomyopathy F Waagstein Lancet 342, 1941-1946, 1993 | 323 | 1993 |
| & Lidén, E.(2011). Person-centered care—Ready for prime time I Ekman, K Swedberg, C Taft, A Lindseth, A Norberg, E Brink European journal of cardiovascular nursing 10 (4), 248-251, 0 | 67 | |
| 1 Efficay and Safety of Interventions: The Importance of International Clinical Trials (Clinical Trials in Global Era, Roundtable Discussion 2 (RT-2)(H), The 73rd Annual … S Karl Circulation journal: official journal of the Japanese Circulation Society 73 …, 2009 | | 2009 |
| 1012-103 Blood pressure changes do not influence the beneficial effects of carvedilol compared to metoprolol in the patients with heart failure: Results from COMET (carvedilol … M Metra, A Di Lenarda, P Hanrath, M Komajda, B Lutiger, JG Cleland, ... Journal of the American College of Cardiology 5 (43), A157, 2004 | 1 | 2004 |
| 1012-121 Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the carvedilol or metoprolol … M Metra, JG Cleland, A Di Lenarda, P Hanrath, M Komajda, B Lutiger, ... Journal of the American College of Cardiology 43 (5S1), A157-A157, 2004 | 3 | 2004 |
| 10most wanted PA Poole-Wilson, K Swedberg, JGF Cleland The Lancet 363, 2004 | | 2004 |
| 10most wanted T Lagro-Janssen, WW Rosser, C van Weel, JC Chang, EC Wooten, ... Blood 84, 2068-101, 1994 | | 1994 |
| 10most wanted PA Poole-Wilson, K Swedberg, JGF Cleland Circulation 101, 1895-98, 2000 | | 2000 |
| 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from … JJ McMurray, CC Lang, K Swedberg, J Östergren, CB Granger, ... Journal of the American College of Cardiology 5 (43), A197, 2004 | 2 | 2004 |
| 1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM K Swedberg, M Pfeffer, A Cohen-Solal, A Ducharme, C Granger, ... Journal of the American College of Cardiology 43 (5S1), A222-A222, 2004 | 46 | 2004 |
| 1327 Patient characteristics, treatment, prognosis and adherence to guidelines in patients with left-ventricular systolic dysfunction as compared to preserved left-ventricular … MJ Lenzen, M Komajda, WS op Reimer, E Boersma, F Follath, ... European Heart Journal 5 (24), 252, 2003 | | 2003 |
| 1446 Assessing Dyspnoea in Patients with Chronic Heart Failure—Does Gender Make a Difference? I Ekman, M Olofsson, K Boman, N Aires, K Swedberg European Journal of Cardiovascular Nursing 4 (1), 65-66, 2005 | | 2005 |
| 183 Carvedilol has a better protective effect against major vascular events than metoprolol in heart failure‐Results from the COMET study W Remme, J Cleland, A DiLenarda, P Hanrath, M Komajda, B Lutiger, ... European Journal of Heart Failure Supplements 3, 38-38, 2004 | | 2004 |
| 184 Effect of long‐term treatment with carvedilol compared to metoprolol on heart failure morbidity and diabetes in COMET C Torp‐Pedersen, J Cleland, A DiLenarda, P Hanrath, M Komajda, ... European Journal of Heart Failure Supplements 3, 38-39, 2004 | 8 | 2004 |
| 187 Exchange of beta blocking therapy in heart failure patients. Experiences from the post study phase of COMET (The Carvedilol or Metoprolol European Trial) A DiLenarda, J Cleland, P Hanrath, M Komajda, B Lutiger, M Metra, ... European Journal of Heart Failure Supplements 3, 39-40, 2004 | 1 | 2004 |
| 188 Incidence and type of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure; results from COMET P Poole‐Wilson, J Cleland, A DiLenarda, P Hanrath, M Komajda, ... European Journal of Heart Failure Supplements 3, 40-40, 2004 | | 2004 |
| 2 cases of cardiogenic shock in acute heart infarct treated with large doses of corticosteroids K Swedberg Lakartidningen 70 (40), 3428, 1973 | | 1973 |
| 2-year survival with atenolol administration. K Swedberg, H Wedel Evidence-based Cardiovascular Medicine 2 (1), 33; discussion 33-33 …, 1998 | 3 | 1998 |
| 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart … Authors/Task Force Members, K Dickstein, PE Vardas, A Auricchio, ... Europace 12 (11), 1526-1536, 2010 | 1194 | 2010 |
